|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E)-mutated DNA was quantified in plasma samples and in cancer sections by quantitative real-time polymerase chain reaction (qPCR).
|
24858900 |
2014 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We calculated and compared the diagnostic performances of cytology and cytology with BRAF(V600E) mutation analysis to detect malignancy among thyroid nodules according to ultrasound features and size.
|
23717622 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We used a polymerase chain reaction-based assay to detect mutations in BRAF (V600E) and in KRAS in 2720 stage III cancer samples, collected prospectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147).
|
25305506 |
2015 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aims of this study were to evaluate the utility of US-guided FNAB in the diagnostic assessment of nodules with or without clinical/US features suggestive for malignancy and to investigate the additional contribution of BRAF V600E mutation analysis in the detection of differentiated thyroid cancer.
|
22535974 |
2012 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In serrated adenomas, BRAF-V600E mutation does not seem to be associated with age and sex, with the prevalence of dysplasia and cancer and with the morphology of the dysplastic component.
|
30815911 |
2019 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
|
25156883 |
2014 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of BRAF(V600E) mutation had limited value in diagnoses of malignancy in follicular neoplasms but can ascertain malignancy in subset of suspicious for malignancy FNABs.
|
21948220 |
2011 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The increased incidence of cancer in FDRs of index CRC patients with the p.V600E BRAF mutation may be explained by a genetic predisposition to develop cancer through the serrated pathway of colorectal carcinogenesis.
|
20570909 |
2010 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using patient-derived (V600E)BRAF melanoma cells, we found that low-glutamine-induced histone hypermethylation resulted in cancer cell dedifferentiation and resistance to BRAF inhibitor treatment, which was largely mediated by methylation on H3K27, as knockdown of the H3K27-specific demethylase KDM6B and the methyltransferase EZH2 respectively reproduced and attenuated the low-glutamine effects in vitro and in vivo.
|
27617932 |
2016 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A BRAF V600E mutation was identified in 15% of PD-L1-positive malignancies.
|
31821747 |
2020 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
|
29422527 |
2018 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Right-sided colon tumors more frequently have BRAF (p.V600E) mutations and have higher methylation grades when compared to left-sided malignancies.
|
24244575 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our finding of tumor-specific patterns of NR expression, as well as significant differences in NR expression between BRAF(V600E) and wild type BRAF PTC, provides a basis for further mechanistic studies and highlights potential novel therapeutic targets for this malignancy.
|
24559275 |
2014 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Unlike BRAF(V600E), the most common mutation, K601E is strongly associated with follicular-patterned cancer, particularly with the encapsulated follicular variant of PTC, and may also be found in follicular thyroid carcinomas.
|
26422023 |
2016 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two of 5 patients with BRAF V600E had progression, including 1 GT-UMP with local recurrence and 1 malignant tumor with enlarging residual disease.
|
28834810 |
2017 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
With advances in RAF inhibitors and second-generation inhibitors including encorafenib and vemurafenib, which have been approved for treating BRAF-V600E malignancies, the combinatorial therapeutic strategies of RAF inhibitors elicit remarkable responses in patients with BRAF-V600E mCRC.
|
30122982 |
2018 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Screening for BRAF c.1799T>A p.V600E is especially useful for those with malignant tumors, because it is one of the most-druggable targets.
|
26360803 |
2016 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The frequency of malignancy and the BRAF(V600E) mutation were compared between suspicious and probably benign nodules on US and between groups 1 and 2.
|
20945104 |
2011 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, our results suggest that DETD-35 may be useful as a therapeutic or adjuvant agent against BRAF(V600E) mutant and acquired vemurafenib resistance melanoma.Mol Cancer Ther; 15(6); 1163-76.©2016 AACR.
|
27048951 |
2016 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the association of BRAF(V600E) mutation with US features of thyroid nodules in predicting the malignancy of thyroid nodules in Korean patients.
|
21707687 |
2011 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation was associated with an advanced stage of cancer (P = .045) and was found to be associated with poor prognostic factors.
|
23690118 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas.
|
21107323 |
2010 |